Subscribe to news feed
Bladder Cancer Trials
Phase 2 Clinical Trial in Metastatic Bladder Cancer
Borealis-1™ is a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. Borealis-1 aims to evaluate the potential benefit of OGX-427 in combination with standard of care first-line chemotherapy in patients with metastatic bladder cancer by measuring the treatments’ impact on survival.
NOW ENROLLING: Learn more about the Borealis-1 Trial.
Phase 2 Clinical Trial in Metastatic Bladder Cancer
Borealis-2™ is an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy. Borealis-2 is designed to evaluate the potential benefit of adding OGX-427 to standard of care second-line chemotherapy by measuring the treatments’ impact on survival. The trial is sponsored by the Hoosier Oncology Group.
NOW ENROLLING: Learn more about the Borealis-2 Trial.
Phase 1 Clinical Trial in Superficial or Non-Muscle Invasive Bladder Cancer
This investigator-initiated, open-label Phase 1 trial is designed to evaluate the potential benefit of OGX-427 when directly infused into the bladder of patients with superficial or non-invasive bladder cancer. The trial is sponsored by the National Cancer Institute of Canada.
NOW ENROLLING: Learn more about the OGX-427 Phase 1 Bladder Cancer Trial.
